Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27382220 | 0.89 | OPRD1 (0.51) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL24642302 | 0.89 | CTSS (0.50) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL25751083 | 0.89 | CTSS (0.50) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL27361383 | 0.87 | OPRD1 (0.49) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL18477606 | 0.87 | OPRD1 (0.51) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL26512014 | 0.87 | CTSS (0.46) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL26575093 | 0.86 | CTSS (0.47) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL27101824 | 0.85 | CTSS (0.53) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL24642881 | 0.85 | CTSS (0.46) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL26499164 | 0.84 | CTSB (0.46) | CTSSCTSLCTSBOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022262789-A1 | ANTITUMOR COMPOUND AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | CTSS 1855/4885CTSL 112/4885CTSB 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.